University of Miami Sylvester Comprehensive Cancer Center

 

University of Miami Sylvester Comprehensive Cancer Center
A

Evaluating Zanubrutinib + Tafasitamab in MCL

By University of Miami Sylvester Comprehensive Cancer Center FEATURING Alvaro Alencar
By University of Miami Sylvester Comprehensive Cancer Center FEATURING Alvaro Alencar
25 views
May 7, 2024
Comments 0
Login to view comments. Click here to Login

Featured Video

19:39
Pfizer Hematology

The First Treatment Choice Matters

Feat. A. Ip

Featured Video

18:30
Pfizer Hematology

Expert Case Review: A Treatment Option for Adult Patients With Stage…

Feat. A. Whiteley
Lymphoma
10:08

New

ASH 2024 Insights: Loncastuximab Tesirine and Rituximab in High-Risk…

2024 ASH Annual Meeting Insights Hub

J. Alderuccio

22:04

MZL: Current Management and Emerging Therapeutics

University of Miami Sylvester Comprehensive Cancer Center

I. Lossos

59 views
08:42

Optimizing Early Stage HL Treatment: Eliminating or Replacing Radiat…

University of Miami Sylvester Comprehensive Cancer Center

C. Moskowitz

30 views
10:52

Current Treatment of 1L Hodgkin Lymphoma

University of Miami Sylvester Comprehensive Cancer Center

C. Moskowitz

500 views
07:41

Using BTKis in MCL Today

University of Miami Sylvester Comprehensive Cancer Center

A. Alencar

66 views
09:10

Evaluating Zanubrutinib + Tafasitamab in MCL

University of Miami Sylvester Comprehensive Cancer Center

A. Alencar

25 views
27:01

Hodgkin Lymphoma - Metabolic Tumor Volume as Prognostic Factor, Role…

University of Miami Sylvester Comprehensive Cancer Center

C. Moskowitz

268 views